Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy

Award Number: R44CA268541
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy - Vivreon Biosciences, LLC 4940 Carroll Canyon Rd. Suite 110 San Diego, CA 92121 milton@vivreonbiosciences.com Vivreon Biosciences, LLC, NCI SBIR Direct to Phase II, Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications, PA-21-259 IND-Enabling Toxicology for VV2003, a Novel CRAC Channel Therapeutic, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy Project Summary Vivreon Biosciences is pleased to apply for NCI SBIR Solicitation PA-21-259. Vivreon is an innovative life sciences company that is developing a novel small molecule Ca2+ channel inhibitor, VV2003, to improve outcomes in persons undergoing immune checkpoint inhibitor immunotherapy. Checkpoint inhibitors have improved overall survival in numerous cancers, but enterocolitis has emerged as the most frequent dose-limiting toxicity associated with these therapies. Checkpoint inhibitor-induced colitis is currently treated with immunosuppressive therapy, which blunts the tumor-killing potential of the checkpoint inhibitor immunotherapy and is administered following checkpoint therapy discontinuation. VV2003 is an oral candidate therapeutic designed to selectively and safely block checkpoint inhibitor-induced enterocolitis without systemic immunosuppressive side effects. It is intended to be used concomitantly with checkpoint inhibitors, allowing immunotherapy to continue, separating it from other investigational therapies. Vivreon seeks NCI Phase 2 funding for investigational new drug (IND)-enabling good laboratory practice (GLP) toxicity, safety, and genotoxicity studies. Specifically, NCI funding will go towards dose range finding toxicity studies, two-species GLP 28-day toxicity studies, GLP safety pharmacology and genetic toxicology, GLP pharmacological respiratory safety assessment, and GLP cardiovascular telemetry. Activities in this proposal will run in parallel with chemistry manufacturing and controls (CMC) processes that will be funded by Vivreon’s Seed investor. Completion of these studies will support and be written up in an IND application, with the final milestone being IND submission to the US Food and Drug Administration (FDA).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	VIVREON BIOSCIENCES LLC	6199 CORNERSTONE CT E STE 101	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	2	4/3/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	2	11/20/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $502,010 )
2024	2024	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	2	5/21/2024	NON-COMPETING CONTINUATION	$502,010
														Subtotal = $502,010

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	8/4/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $1,371,030 )
2022	2022	VIVREON BIOSCIENCES, LLC	4940 CARROLL CANYON RD STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	5/31/2022	NEW	$1,371,030
														Subtotal = $1,371,030

Grand Total All Awards = $1,873,040

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy

Award Number: R44CA268541

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer